Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure

INTRODUCTION: A clinical trial (RACAT) reported the noninferiority of triple therapy compared to biologic agents (etanercept + methotrexate), and previous studies confirmed that biologic disease-modifying antirheumatic drugs (bDMARDs) are more expensive but less beneficial than triple therapy for pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, SiNi, Li, JianHe, Peng, LiuBao, Li, YaMin, Wan, XiaoMin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217385/
https://www.ncbi.nlm.nih.gov/pubmed/33772743
http://dx.doi.org/10.1007/s40744-021-00300-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217385/
https://www.ncbi.nlm.nih.gov/pubmed/33772743
http://dx.doi.org/10.1007/s40744-021-00300-4

Ejemplares similares